



(86) Date de dépôt PCT/PCT Filing Date: 2012/05/21
(87) Date publication PCT/PCT Publication Date: 2013/11/14
(45) Date de délivrance/Issue Date: 2017/11/28
(85) Entrée phase nationale/National Entry: 2014/11/03
(86) N° demande PCT/PCT Application No.: US 2012/038772
(87) N° publication PCT/PCT Publication No.: 2013/169273
(30) Priorité/Priority: 2012/05/07 (US13/465,873)

(51) Cl.Int./Int.Cl. *A61K 8/9794* (2017.01),
A61K 38/05 (2006.01), *A61K 38/06* (2006.01),
A61K 8/60 (2006.01), *A61K 8/64* (2006.01),
A61K 8/9789 (2017.01), *A61P 17/00* (2006.01),
A61Q 19/08 (2006.01), *A61Q 7/00* (2006.01)

(72) Inventeurs/Inventors:
MAJEED, MUHAMMED, US;
NAGABHUSHANAM, KALYANAM, US

(73) Propriétaire/Owner:
MAJEED, MUHAMMED, US

(74) Agent: NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : FORMULATIONS DE SELENOPEPTIDE SYNERGIQUES POUR LA PROTECTION DE CELLULES DE
PAPILLES DERMiques

(54) Title: SYNERGISTIC SELENOPEPTIDE FORMULATIONS FOR THE PROTECTION OF DERMAL PAPILLA CELLS

(57) Abrégé/Abstract:

The present invention discloses selenium peptide based synergistic compositions for the protection (morphology and viable numbers) of dermal papilla cells. The synergistic compositions disclosed in the present invention comprise (a) 1-O-galloyl- β -D-glucose (β -glucogallin) or 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates (b) concentrate of liquid endosperm of *Cocos nucifera* and (c) selenopeptides.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2013/169273 A1

(43) International Publication Date
14 November 2013 (14.11.2013)

(51) International Patent Classification:

A61K 38/00 (2006.01) *A61K 8/97* (2006.01)
A61K 8/44 (2006.01) *A61Q 7/00* (2006.01)
A61K 8/64 (2006.01) *A61P 17/00* (2006.01)

(21) International Application Number:

PCT/US2012/038772

(22) International Filing Date:

21 May 2012 (21.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13/465,873 7 May 2012 (07.05.2012) US

(72) Inventor; and

(71) Applicant : MAJEED, Muhammed [US/US]; Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520-5321 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): NAGABHUSHANAM, Kalyanam [US/US]; Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520-5321 (US).

(74) Common Representative: NAGABHUSHANAM, Kalyanam; Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520-5321 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: SYNERGISTIC SELENOPEPTIDE FORMULATIONS FOR THE PROTECTION OF DERMAL PAPILLA CELLS

(57) Abstract: The present invention discloses selenium peptide based synergistic compositions for the protection (morphology and viable numbers) of dermal papilla cells. The synergistic compositions disclosed in the present invention comprise (a) 1-O-galloyl- β -D-glucose (β -glucogallin) or 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates (b) concentrate of liquid endosperm of *Cocos nucifera* and (c) selenopeptides.



WO 2013/169273 A1

SYNERGISTIC SELENOPEPTIDE FORMULATIONS FOR THE PROTECTION OF DERMAL PAPILLA CELLS

[PARA 001] FIELD OF THE INVENTION

[PARA 002] The present invention relates to protective compositions for dermal papilla cells. More specifically, the present invention relates to formulations comprising synergistic compositions that include (a) β -glucogallin or β -glucogallin and gallates, (b) concentrate of liquid endosperm of *Cocos nucifera* and (c) selenopeptides, for the protection of dermal papilla cells.

[PARA 003] DESCRIPTION OF PRIOR ART

[Para 004] Dermal papilla cells are mesenchymal cells of the skin that not only regulate development of a hair peg but also constitute a reservoir of multi-potent stem cell lineages (Driskell et al., Journal of Cell Science (2011) 124, pp 1179-1182). These stem cell lineages function as “tissue engineers” and are valued assets in regenerative medicine. Dermal papilla cells expressing the stem cell marker genes Sox 2 (transcription factor essential for the preservation of the pluripotent phenotype of stem cells) evince ability to self renew, induce hair peg formation and differentiate into fibroblasts that aid the formation of skin extracellular matrix. In fact, dermal papilla plays a very vital role in replacement of senescent fibroblasts with healthy ones thereby maintaining fibroblast numbers. Recent studies (Arnold I. Caplan, Diego Correa. The MSC: An Injury Drugstore. Cell Stem Cell, Volume 9, Issue 1, 11-15, 8 July 2011 DOI: 10.1016/j.stem.2011.06.008) also indicate the role of mesenchymal stem cells (MSCs) as powerful “innate antidotes” in terms of their ability to (i) moderate unwarranted inflammatory responses that follow tissue damage, thus facilitating a conducive environ for automatic tissue repair; and (b) produce proteins that kill bacteria like *Escherichia coli* and *Staphylococcus aureus* and thus enhancing microbial clearance from the body systems. In view of the aforementioned diverse functions of dermal papilla cells, it is important to maintain the healthy state of these cells in terms of numbers and morphology and also protect their stem cell characteristics.

[PARA 005] The ability of selenopeptides gamma-L-glutamyl-Selenomethyl-L-selenocysteine and γ -L-glutamyl-L-Selenomethionine to enhance vascular endothelial growth factor (VEGF) and its 5-alpha reductase activity was documented in US8003614 (Majeed et al.). Surprisingly,

the present inventors note that selenopeptides though being poor protectants of dermal papilla cells by themselves, synergistically enhance the dermal papilla protective ability of the formulations disclosed by Majeed et al. in US 20110033565, said formulations comprising compositions that include (a) 1-O-galloyl- β -D-glucose (β -glucogallin) or β -glucogallin and gallates, and (b) concentrate of liquid endosperm of *Cocos nucifera*.

[PARA 006] As a result, synergistic selenopeptide formulations of the present invention find considerable application in maintaining morphologically healthy dermal papilla cells in sufficient numbers and thereby protecting the stem cell characteristics of the same.

[PARA 007] It is the principle objective of the present invention to disclose protective formulations comprising synergistic compositions that include (a) β -glucogallin or β -glucogallin and gallates, (b) concentrate of liquid endosperm of *Cocos nucifera* and (c) selenopeptides that protect dermal papilla cells from stress signals and associated applications thereof.

[PARA 008] The present invention fulfills the stated objective and provides further related advantages.

[PARA 009] **SUMMARY OF THE INVENTION**

[PARA 0010] The present invention discloses formulations comprising synergistic compositions including (a) β -glucogallin or β -glucogallin and gallates (b) concentrate of liquid endosperm of *Cocos nucifera* and (c) selenopeptides for the protection of dermal papilla cells from stress signals.

[PARA 0011] **BRIEF DESCRIPTION OF DRAWINGS**

[PARA 0012] FIG.1 shows the photomicrographs of 0.5% concentrate of liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40%w/w of total dissolved solids unable to protect dermal papilla cells singly.

[PARA 0013] FIG.2 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-1 (compositions comprising at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) in comparison with UVB irradiated untreated cells. PC-1 is unable to

protect dermal papilla cells from UVB dosage above 0.43 J/cm^2 . Cell damage in PC-1 treated cells occurs at UVB dosage of 0.648 J/cm^2 (shown as part of FIG.4).

[PARA 0014] FIG.3 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-2 (compositions comprising at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% to greater than 50% w/w of gallates) in comparison with UVB irradiated untreated cells. PC-2 is unable to protect dermal papilla cells from UVB dosage above 0.43 J/cm^2 . Cell damage in PC-2 treated cells occurs at UVB dosage of 0.648 J/cm^2 (shown as part of FIG.5).

[PARA 0015] FIG.4 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-3 (PC-1+0.5% concentrate of liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40% w/w of total dissolved solids). PC-3 protects dermal papilla cells from UVB exposure levels of up to only 0.648 J/cm^2 and not 0.8 J/cm^2 . Cell death at 0.8 J/cm^2 is shown in the figure.

[PARA 0016] FIG.5 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-4 (PC-2+0.5% concentrate of liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40%w/w of total dissolved solids). PC-4 protects dermal papilla cells at UVB exposure levels of only up to 0.648 J/cm^2 and not 0.8 J/cm^2 . Cell death at 0.8 J/cm^2 is shown in the figure.

[PARA 0017] FIG.6 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-5 (PC-3 + 0.001% w/w of γ -L-glutamyl-Selenomethyl-L-selenocysteine). PC-5 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation of 0.8 J/cm^2 .

[PARA 0018] FIG.7 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-6 (PC-3 + 0.001% w/w of γ -L-glutamyl-L-Selenomethionine). PC-6 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation of 1.0 J/cm^2 .

[PARA 0019] FIG.8 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-7 (PC-4+0.001%w/w of γ -L-glutamyl-Selenomethyl-L-

selenocysteine). PC-7 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation of 0.8 J/cm^2 .

[PARA 0020] FIG.9 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-8 (PC-4+0.001% w/w of γ -L-glutamyl-L-Selenomethionine). PC-8 provides significant (95%) protection to dermal papilla cells exposed to very high doses of UVB radiation of 1.0 J/cm^2 .

[PARA 0021] FIG.10 shows the photomicrographs of UVB irradiated dermal papilla cells treated with protective formulation PC-9 (0.001% w/w of γ -L-glutamyl-Selenomethyl-L-selenocysteine (FIG.10a) or 0.001% w/w of γ -L-glutamyl-L-Selenomethionine (FIG.10b)). PC-9 provides no protection to dermal papilla cells exposed to even low level of UVB radiation (UVB dose of 0.432 J/cm^2).

[PARA 0022] DESCRIPTION OF THE INVENTION

[PARA 0023] The present invention relates to dermal papilla cell protective formulation comprising synergistic composition, said composition including 1-O-galloyl- β -D-glucose (β -glucogallin), concentrate of liquid endosperm of *Cocos nucifera* and selenopeptides.

[PARA 0024] In another embodiment of the invention, the synergistic composition comprises at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin).

[PARA 0025] In yet another embodiment of the invention, the synergistic composition comprises 0.5% w/w of the concentrate from the liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40% w/w of total dissolved solids.

[PARA 0026] In still another embodiment of the invention, the synergistic composition comprises 0.001% w/w of selenopeptides.

[PARA 0027] In still another embodiment of the invention, the selenopeptide is γ -L-glutamyl-Selenomethyl-L-selenocysteine.

[PARA 0028] In still another embodiment of the invention, the selenopeptide is γ -L-glutamyl-L-Selenomethionine.

[PARA 0029] The present invention relates to dermal papilla cell protective formulation comprising synergistic composition, said composition including 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates, concentrate of liquid endosperm of *Cocos nucifera* and selenopeptides.

[PARA 0030] In still another embodiment of the invention, the synergistic composition comprises at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% to greater than 50% total gallates including mucic acid 1, 4-lactone-5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid.

[PARA 0031] In still another embodiment of the invention, the synergistic composition comprises 0.5% w/w of the concentrate from the liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40% w/w of total dissolved solids.

[PARA 0032] In still another embodiment of the invention, the synergistic composition comprises 0.001% w/w of selenopeptides.

[PARA 0033] In still another embodiment of the invention, the selenopeptide is γ -L-glutamyl-Selenomethyl-L-selenocysteine.

[PARA 0034] In still another embodiment of the invention, the selenopeptide is γ -L-glutamyl-L-Selenomethionine.

[PARA 0035] The present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact the dermal papilla cells and the protective formulations as defined herein.

[PARA 0036] The present invention also relates to a method of maintaining the morphology and numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact the dermal papilla cells and the protective formulation as defined herein.

[PARA 0037] In still another embodiment of the invention, the dermal papilla cells include dermal stem/progenitor cells.

[PARA 0038] In the most preferred embodiment, the present invention relates to the following synergistic selenopeptide formulations for the protection of dermal papilla cells.

[PARA 0039] (A) PC-5 comprising synergistic compositions, said compositions including (a) 1-O-galloyl- β -D-glucose (β -glucogallin); (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) γ -L-glutamyl-Selenomethyl-L-selenocysteine. In specific embodiments, said compositions comprise (a) at least 10% w/w 1-O-galloyl- β -D-glucose (β -glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of γ -L-glutamyl-Selenomethyl-L-selenocysteine.

[PARA 0040] (B) PC-6 comprising synergistic compositions, said compositions including (a) 1-O-galloyl- β -D-glucose (β -glucogallin); (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) γ -L-glutamyl-L-Selenomethionine. In specific embodiments, said compositions comprise (a) at least 10% w/w 1-O-galloyl- β -D-glucose (β -glucogallin); (b) 0.5% w/w of concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of γ -L-glutamyl-L-Selenomethionine.

[PARA 0041] (C) PC-7 comprising synergistic compositions, said compositions including, (a) 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates; (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) γ -L-glutamyl-Selenomethyl-L-selenocysteine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w of concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of γ -L-glutamyl-Selenomethyl-L-selenocysteine.

[PARA 0042] (D) PC-8 comprising synergistic compositions, said compositions including, (a) 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates; (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) γ -L-glutamyl-L-Selenomethionine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w concentrate of

liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of γ -L-glutamyl-L-Selenomethionine.

[PARA 0043] In other preferred embodiments of the invention, other dipeptides occurring as combinations with other amino acids may be used in the aforesaid synergistic dermal papilla cell protective formulations.

[PARA 0044] In an alternate embodiment, the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact dermal papilla cells and the protective formulation PC-5 comprising synergistic compositions, said compositions including, (a) 1-O-galloyl- β -D-glucose (β -glucogallin); (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) γ -L-glutamyl-Selenomethyl-L-selenocysteine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of γ -L-glutamyl-Selenomethyl-L-selenocysteine.

[PARA 0045] In another alternative embodiment, the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact dermal papilla cells and the protective formulation PC-6 comprising synergistic compositions, said compositions including, (a) 1-O-galloyl- β -D-glucose (β -glucogallin); (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) γ -L-glutamyl-L-Selenomethionine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of γ -L-glutamyl-L-Selenomethionine.

[PARA 0046] In another alternative embodiment, the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact dermal papilla cells and protective formulation PC-7 comprising synergistic compositions, said compositions including, (a) 1-O-galloyl- β -D-glucose (β -

glucogallin) and gallates; (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) γ -L-glutamyl-Selenomethyl-L-selenocysteine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% w/w to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of γ -L-glutamyl-Selenomethyl-L-selenocysteine.

[PARA 0047] In another alternative embodiment, the present invention also relates to a method of increasing the tolerance of dermal papilla cells to stress signals, said method comprising step of bringing into contact dermal papilla cells and protective formulation PC-8 comprising of synergistic compositions, said compositions including, (a) 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates; (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) γ -L-glutamyl-L-Selenomethionine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% w/w to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of γ -L-glutamyl-L-Selenomethionine.

[PARA 0048] In yet another alternative embodiment, the present invention also relates to a method of maintaining the morphology and numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact dermal papilla cells and the protective formulation PC-5 comprising synergistic compositions, said compositions including, (a) 1-O-galloyl- β -D-glucose (β -glucogallin); (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) γ -L-glutamyl-Selenomethyl-L-selenocysteine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of γ -L-glutamyl-Selenomethyl-L-selenocysteine.

[PARA 0049] In yet another alternative embodiment, the present invention also relates to a method of maintaining the morphology and numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact dermal papilla cells and the protective formulation PC-6 comprising synergistic compositions, said compositions including, (a) 1-O-galloyl- β -D-glucose (β -glucogallin); (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) γ -L-glutamyl-L-Selenomethionine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin); (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) 0.001% w/w of γ -L-glutamyl-L-Selenomethionine.

[PARA 0050] In another alternative embodiment, the present invention also relates to a method of maintaining morphology and numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact dermal papilla cells and protective formulation PC-7 comprising synergistic compositions, said compositions including, (a) β -glucogallin and gallates; (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) γ -L-glutamyl-Selenomethyl-L-selenocysteine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% w/w to greater than 50% w/w of total gallates including mucic acid 1, 4-lactone-5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of γ -L-glutamyl-Selenomethyl-L-selenocysteine.

[PARA 0051] In another alternative embodiment, the present invention also relates to a method of maintaining the morphology and viable numbers of dermal papilla cells during exposure to stress signals, said method comprising step of bringing into contact dermal papilla cells and protective formulation PC-8 comprising synergistic compositions, said compositions including, (a) β -glucogallin and gallates; (b) concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids; and (c) γ -L-glutamyl-L-Selenomethionine. In specific embodiments, said compositions comprise (a) at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% w/w to greater than 50% w/w of total gallates

including mucic acid 1, 4-lactone-5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid; (b) 0.5% w/w concentrate of liquid endosperm of *Cocos nucifera*, said concentrate including at least 40% dissolved solids and (c) 0.001% w/w of γ -L-glutamyl-L-Selenomethionine.

[PARA 0052] In a more specific embodiment, the dermal papilla cells mentioned herein above comprise dermal stem/progenitor cells.

[PARA 0053] EXAMPLE I

[PARA 0054] GENERAL PROCEDURE

[PARA 0055] Human dermal papilla cells were plated into a 96 well flat bottomed clear micro plate at a seeding density of 5000 cells per well. The 24 hour monolayer of cells was exposed to UVB dosages ranging from 0.0072 J/cm² to 1.0 J/cm² (stress signal) with or without sample (protective formulations) treatment. After exposure, the cells were incubated in a CO₂ incubator for 48 hours and developed by NRU (Neutral Red Uptake) staining techniques to analyze cell viability. The absorbance due to viable cells is read at 492nm in a micro plate reader.

[PARA 0056] Sample tested- 0.5% concentrate of liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40% w/w of total dissolved solids.

[PARA 0057] FIG.1 shows that the 0.5% concentrate of liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40%w/w of total dissolved solids is unable to protect dermal papilla cells singly at 0.43 J/cm² and 0.648 J/cm² UVB exposure levels.

[PARA 0058] Sample tested: PC-1 in comparison with UVB irradiated untreated cells.

[PARA 0059] FIG.2 shows PC-1 by itself is able to protect dermal papilla cells from UVB exposure levels of only up to 0.43 J/cm².

[PARA 0060] Sample tested: PC-2 in comparison with UVB irradiated untreated cells.

[PARA 0061] FIG.3 shows PC-2 by itself is able to protect dermal papilla cells from UVB exposure levels of only up to 0.43 J/cm².

[PARA 0062] Sample tested: PC-3

[PARA 0063] FIG.4 shows that PC-3 is able to protect dermal papilla cells from UVB exposure levels of up to 0.648 J/cm^2 and death of PC-3 treated dermal papilla cells is seen at UVB exposure level of 0.8 J/cm^2 .

[PARA 0064] Sample tested: PC-4.

[PARA 0065] FIG.5 shows that PC-4 is able to protect dermal papilla cells from UVB exposure levels of up to at 0.648 J/cm^2 UVB exposure levels and death of PC-4 treated dermal papilla cells is seen at UVB exposure level of 0.8 J/cm^2 .

[PARA 0066] Sample tested-PC-9

[PARA 0067] FIG.10 shows that neither γ -L-glutamyl-Selenomethyl-L-selenocysteine (FIG.10a) nor γ -L-glutamyl-L-Selenomethionine (FIG.10b) by themselves are able to protect dermal papilla cells even at low levels of UVB exposure (0.432 J/cm^2).

[PARA 0068] Sample tested: PC-5

[PARA 0069] FIG.6 shows that PC-5 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation levels of 0.8 J/cm^2 .

[PARA 0070] Sample tested: PC-6

[PARA 0071] FIG.7 shows that PC-6 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation levels of 1.0 J/cm^2 .

[PARA 0072] Sample tested: PC-7

[PARA 0073] FIG.8 shows that PC-7 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation levels of 0.8 J/cm^2 .

[PARA 0074] Sample tested: PC-8

[PARA 0075] FIG.9 shows that PC-8 provides significant (95%) protection to dermal papilla cells exposed to UVB radiation levels of 1.0 J/cm^2 .

[PARA 0076] The effect of various samples used in the invention is presented herein below as Table 1.

Table 1

Samples (Protective formulations tested)	UVB irradiation levels on dermal papilla cells		
	0.432 J/cm ²	0.648 J/cm ²	0.8 or 0.1 J/cm ²
Concentrate of liquid endosperm of <i>Cocos nucifera</i>	No protection (cell death observed)	-	-
PC-1 Compositions comprising at least 10% w/w or greater of 1-O-galloyl- β -D-glucose (β -glucogallin)	Provides protection	No protection (Causes cell damage)	-
PC-2 Compositions comprising at least 10% w/w or greater of β -glucogallin and 50% w/w or greater than 50% w/w of gallates.	Provides protection	No protection (Causes cell damage)	-
PC-3 (PC-1 + concentrate of liquid endosperm of <i>Cocos nucifera</i>)	Provides protection	Provides protection	No protection
PC-4 (PC-2 + concentrate of liquid endosperm of <i>Cocos nucifera</i>)	Provides protection	Provides protection	No protection
γ -L-glutamyl-Selenomethyl-L-selenocysteine (PC-9)	No protection	-	-
γ -L-glutamyl-L-Selenomethionine (PC-9)	No protection	-	-
PC-5 (PC-3 + γ -L-glutamyl-Selenomethyl-L-selenocysteine)	Provides protection	Provides protection	Provides protection
PC-6 (PC-3 + γ -L-glutamyl-L-Selenomethionine)	Provides protection	Provides protection	Provides protection
PC-7 (PC-4 + γ -L-glutamyl-Selenomethyl-L-selenocysteine)	Provides protection	Provides protection	Provides protection
PC-8 (PC-4 + γ -L-glutamyl-L-Selenomethionine)	Provides protection	Provides protection	Provides protection

[PARA 0077] From the results, it is evident that

- A. The selenopeptides and concentrate of liquid endosperm of *Cocos nucifera* singly do not confer protection to dermal papilla cells at even low levels of UVB exposure (0.432 J/cm^2).
- B. β -glucogallin or β -glucogallin and gallates are able to provide protection of dermal papilla cells only up to UVB exposure levels of 0.432 J/cm^2 .
- C. Although the combination of concentrate of liquid endosperm of *Cocos nucifera* and β -glucogallin or β -glucogallin and gallates provides protection to dermal papilla cells from UVB exposure levels up to 0.648 J/cm^2 , said protection does not extend beyond this level. Rather, the tolerance level to the tested stress signal is 0.648 J/cm^2 .
- D. However, the combination of (a) β -glucogallin or β -glucogallin and gallates, (b) concentrate of liquid endosperm of *Cocos nucifera* and (c) selenopeptides extend protection to dermal papilla cells at UVB exposure levels even beyond 0.648 J/cm^2 , specifically between $0.8\text{-}1.0 \text{ J/cm}^2$. Selenopeptides though being poor protectants of dermal papilla cells by themselves, synergistically enhance the dermal papilla cell protective ability of formulations comprising (a) 1-O-galloyl- β -D-glucose (β -glucogallin) or 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates and (b) the concentrate of liquid endosperm of *Cocos nucifera*. Thus an unexpected improved tolerance of dermal papilla cells to stress signals conferred by the synergistic combination of (a) 1-O-galloyl- β -D-glucose (β -glucogallin) or 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates, (b) concentrate of liquid endosperm of *Cocos nucifera* and (c) selenopeptides is clear from the instant invention. The composition of the present invention shows superior activity when compared to individual components or other combinations.

[PARA 0078] It is to be understood that though the present invention has been described with reference to specific preferred examples, it is possible for persons having ordinary skill in the art to make modifications and variations without departing from the spirit of the invention. Accordingly, the foregoing disclosure should be interpreted as illustrative only and not in a limiting sense. The present invention is limited only by the scope of appended claims which also includes the scope of equivalents.


Claims:

- 1) Dermal papilla cell protective formulation comprising synergistic composition, said composition including 1-O-galloyl- β -D-glucose (β -glucogallin), concentrate of liquid endosperm of *Cocos nucifera* and selenopeptides.
- 2) The formulation of claim 1, wherein said synergistic composition comprises at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin).
- 3) The formulation of claim 1, wherein said synergistic composition comprises 0.5% w/w of the concentrate from the liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40% w/w of total dissolved solids.
- 4) The formulation of claim 1, wherein said synergistic composition comprises 0.001% w/w of selenopeptides.
- 5) The formulation of claim 1, wherein the selenopeptide is γ -L-glutamyl-Selenomethyl-L-selenocysteine.
- 6) The formulation of claim 1, wherein the selenopeptide is γ -L-glutamyl-L-Selenomethionine.
- 7) Dermal papilla cell protective formulation comprising synergistic composition, said composition including 1-O-galloyl- β -D-glucose (β -glucogallin) and gallates, concentrate of liquid endosperm of *Cocos nucifera* and selenopeptides.
- 8) The formulation of claim 7, wherein said synergistic composition comprises at least 10% w/w of 1-O-galloyl- β -D-glucose (β -glucogallin) and greater than 50% total gallates including mucic acid 1, 4-lactone-5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate, mucic acid 1-methyl ester 2-O-gallate and ellagic acid.


- 9) The formulation of claim 7, wherein said synergistic composition comprises 0.5% w/w of the concentrate from the liquid endosperm of *Cocos nucifera*, said concentrate comprising not less than 40% w/w of total dissolved solids.
- 10) The formulation of claim 7, wherein said synergistic composition comprises 0.001% w/w of selenopeptides.
- 11) The formulation of claim 7, wherein the selenopeptide is γ -L-glutamyl-Selenomethyl-L-selenocysteine.
- 12) The formulation of claim 7, wherein the selenopeptide is γ -L-glutamyl-L-Selenomethionine.
- 13) Use of the protective formulation as claimed in claim 1 in contact with dermal papilla cells, for increasing the tolerance of said dermal papilla cells to stress signals.
- 14) Use of the protective formulation as claimed in claim 1 in contact with dermal papilla cells, for maintaining the morphology and numbers of said dermal papilla cells during exposure to stress signals.
- 15) The use of claim 13 or 14, wherein the dermal papilla cells include dermal stem/progenitor cells.
- 16) Use of the protective formulation as claimed in claim 7 in contact with dermal papilla cells, for increasing the tolerance of said dermal papilla cells to stress signals.
- 17) Use of the protective formulation as claimed in claim 7 in contact with dermal papilla cells, for maintaining the morphology and numbers of dermal papilla cells during exposure to stress signals.
- 18) The use of claim 16 or 17, wherein the dermal papilla cells include dermal stem/progenitor cells.

FIG.1

DERMAL PAPILLA CELLS TREATED WITH ONLY 0.5% CONCENTRATE OF LIQUID ENDOSPERM OF *Cocos nucifera*, CONCENTRATE COMPRISING NOT LESS THAN 40%W/W OF TOTAL DISSOLVED SOLIDS.



No UV exposure

UVB exposure of
 0.432 J/cm^2 UVB exposure of
 0.648 J/cm^2


Cell death shown at 0.432 J/cm^2 and 0.648 J/cm^2

FIG. 2

UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-1 (COMPOSITION COMPRISING AT LEAST 10% W/W OR GREATER OF 1-O-galloyl- β -D-glucose (β -glucogallin)) IN COMPARISON WITH UVB IRRADIATED UNTREATED CELLS.

Increasing dosages of UV (J/cm^2)

Row I: Untreated cells



Row II: PC-1 treated cells

PC-1 protects dermal papillary cells from UVB exposure of up to $0.43 \text{ J}/\text{cm}^2$.

FIG. 3

UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-2 (COMPOSITION COMPRISING AT LEAST 10% W/W OR GREATER OF 1-O-galloyl- β -D-glucose (β -glucogallin) and 50% TO GREATER THAN 50% TOTAL GALLATES IN COMPARISON WITH UVB IRRADIATED UNTREATED CELLS.

Increasing dosages of UV (J/cm^2)








Row I: Untreated cells

0.0072

0.0216

0.216

0.432



0.0072

0.0216

0.216

0.432

Row II: PC-2 treated cells


PC-2 protects dermal papillary cells from UVB exposure of up to $0.43 \text{ J}/\text{cm}^2$.

FIG. 4

UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-3 (PC-1 + 0.5% CONCENTRATE OF LIQUID ENDOSPERM OF *Cocos nucifera*, CONCENTRATE COMPRISING NOT LESS THAN 40%W/W OF TOTAL DISSOLVED SOLIDS) .



Cell damage upon treatment
with PC-1 at 0.648 J/cm^2



Intact dermal papilla
cells upon treatment with
PC-3 at 0.648 J/cm^2




PC-3 protects dermal papilla cells at UVB exposure levels of up to only 0.648 J/cm^2 and not 0.8 J/cm^2 (Cell death at 0.8 J/cm^2 is shown here).

FIG. 5


UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-4 (PC-2+0.5% CONCENTRATE OF LIQUID ENDOSPERM OF *Cocos nucifera*, SAID CONCENTRATE COMPRISING NOT LESS THAN 40%W/W OF TOTAL DISSOLVED SOLIDS)



Cell damage upon treatment
with PC-2 at 0.648 J/cm²



Intact dermal papilla
cells upon treatment with
PC-4 at 0.648 J/cm²



PC-4 protects dermal papilla cells at UVB exposure levels of only up to 0.648 J/cm² and not 0.8 J/cm². (Cell death at 0.8 J/cm² is shown here)

FIG. 6

UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-5 (PC-3 + 0.001% OF γ -L-glutamyl-Selenomethyl-L-selenocysteine)




Cells treated with PC-3 alone showing no significant protection from a UV B dose of 0.8 J/cm^2




Cells treated with PC-5 showing significant (95%) protection from a UVB dose of 0.8 J/cm^2

FIG. 7

UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-6 (PC-3 + 0.001% OF γ -L-glutamyl-L-Selenomethionine).




Cells treated with PC-3 alone are not protected from damage by a UV B dose of 0.8 J/cm^2



Cells treated with PC-6 are protected from damage by a UVB dose of 1.0 J/cm^2

FIG. 8

UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-7 (PC-4 + 0.001% OF γ -L-glutamyl-Selenomethyl-L-selenocysteine)




Cell damage upon treatment
with PC-4 at 0.8 J/cm^2




Intact dermal papilla
cells upon treatment with
PC-7 at 0.8 J/cm^2

FIG. 9

UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-8 (PC-4 + 0.001% OF γ -L-glutamyl-L-Selenomethionine).



Cell damage upon treatment
with PC-4 at 0.8 J/cm^2




Intact dermal papilla
cells upon treatment with
PC-8 at 1.0 J/cm^2

FIG.10

UVB IRRADIATED DERMAL PAPILLA CELLS TREATED WITH PROTECTIVE FORMULATION PC-9 (0.001% OF γ -L-glutamyl-Selenomethyl-L-selenocysteine (FIG.10a) OR γ -L-glutamyl-L-Selenomethionine (FIG.10b)).

FIG.10a



Cells treated with PC-9
showing no significant
protection from a lower
UVB dose of 0.432 J/cm^2

FIG.10b



Cells treated with PC-9
showing no significant
protection from a lower
UVB dose of 0.432 J/cm^2